Pulmonary arterial hypertension (PAH) is a chronic disease with poor prognosis and important exercise limitation despite the proliferation of treatment options in the last decade. Chronically increased right ventricular (RV) afterload results in right heart failure and without treatment, rapid clinical deterioration is common. Exercise intolerance is the cardinal feature of the disease impacting upon quality of life and clinical outcome. The pathophysiological mechanisms that lead to reduced exercise capacity in this population are complex with ventriculoarterial uncoupling likely to be the predominant feature. The relative contributions of additional factors that contribute to exercise limitation beyond ventriculoarterial uncoupling have not been characterized. This review addresses these factors with a focus on recent developments and uncertainties. RV maladaptation and the intricate interplay between the heart, abnormal pulmonary vascular bed and peripheral factors such as dysfunction of the respiratory and peripheral muscles are discussed in detail.
INTRODUCTION
Pulmonary arterial hypertension (PAH) is defined as an increase in mean pulmonary arterial pressure (mPAP ≥ 25 mm Hg) and a pulmonary artery wedge pressure of ≤15 mm Hg with a pulmonary vascular resistance (PVR) of >3 Wood units. 1 This is due to luminal obstruction of the distal pulmonary vasculature and if severe, leads to right ventricular (RV) failure and death. Although treatment options have expanded, long-term outcomes are still poor and the 7-year mortality rate for individuals with PAH from the time of diagnosis is~50%. 2 Despite improvements in medical therapy over the last decade, patients still experience symptoms, reduced quality of life (QOL) and high risk of death. 3 Exercise intolerance is the predominant symptom in PAH and exercise capacity has important implications for prognosis, QOL and mortality. This review will examine the inter-related physiological factors that contribute to impaired exercise capacity in patients with PAH and provide contextual evidence for implementing supervised exercise rehabilitation as part of routine care for PAH patients.
Traditionally, the factors impacting upon exercise capacity in PAH were thought to be confined to the cardiopulmonary system with increased RV afterload leading to reduced cardiac output (Qp). Ventriculoarterial uncoupling (mismatch between contractility and afterload) is likely to be the most influential aspect of exercise limitation in the majority of patients. However, the influence of other factors such as peripheral and respiratory muscle function has more recently been recognized 4, 5 (Fig. 1) . Understanding the components that contribute to exercise impairment in this population can assist clinicians in determining effective treatment strategies.
CARDIOPULMONARY EXERCISE TESTING ABNORMALITIES IN PAH
Exercise limitation, manifesting as dyspnoea and fatigue, may become obvious, even in the setting of relatively mild resting haemodynamic derangement measured during cardiac catheterization. These limitations have been illustrated in classical cardiopulmonary exercise testing (CPET) studies in patients with PAH (Fig. 2) . 6 The application of CPET provides objective evaluation of the integrative physiological response and mechanisms of exercise limitation.
CPET findings in PAH typically demonstrate reduced peak oxygen uptake (VO 2 ) with early anaerobic threshold. Peak exercise work rate, heart rate (HR) reserve and oxygen pulse (VO 2 /HR) are significantly reduced. There is ample breathing reserve at peak exercise. Ventilatory inefficiency expressed as an increased VE/VCO 2 (ventilatory equivalent for CO 2 ) slope is a hallmark of PAH and increases in proportion to disease severity. Ventilatory inefficiency is not explained by increased dead space ventilation but rather by increased chemosensitivity leading to exercise hyperventilation and decreased partial pressure of end-tidal carbon dioxide (P ET CO 2 ). Arterial oxygen desaturation may be observed, but this is usually mild; severe oxygen desaturation may indicate right-to-left shunting due to opening of a patent foramen ovale. Typically, peak VO 2 values are reduced tõ 15 mL/kg/min (70% predicted) in mild PAH and 8 mL/kg/min (27% predicted) in severe disease. 6 These values reflect abnormalities in oxygen delivery and the cellular bioenergetics of the heart, lungs and muscles. The specific systems which give rise to these abnormalities will be discussed in detail in this review.
CARDIAC FACTORS AND VENTRICULOARTERIAL UNCOUPLING
RV dysfunction is considered to be one of the major factors limiting exercise capacity and is a hallmark feature of PAH. The RV must overcome chronically increased afterload established by the narrowed and stiffened pulmonary vasculature. Initially, the RV adapts by becoming hypertrophied, preserving systolic function to maintain adequate stroke volume (SV) and Qp. However, as disease progresses, the RV dilates and ventriculoarterial uncoupling occurs. At earlier stages of disease, RV SV may be normal at rest but fail to increase appropriately during exertion, 7 resulting in reduced peak Qp and inability to meet metabolic demands during exercise. Eventually resting RV systolic dysfunction occurs and is an important predictor of adverse outcome. 8, 9 Exertional syncope, an ominous symptom in PAH, develops when Qp is not sufficient to maintain systemic blood pressure in face of the decrease in systemic vascular resistance induced by exercise. A multitude of factors have been implicated in the development of RV failure including ischaemia, metabolic maladaptation and fibrosis. 10 In advanced disease, atrial arrhythmias are common, with an incidence of 25% after 5 years. These hasten clinical deterioration. 
Impaired right ventricular adaptation
The RV has an advanced capacity to remodel against volume overload, in contrast to pressure overload. 12 RV adaptation to increased afterload is a complex process and factors such as the underlying cause of PAH, temporal progression of pulmonary hypertension, gender, genetics and epigenetics interact to determine evolution to a maladaptive response. [13] [14] [15] [16] [17] In Eisenmenger syndrome, despite systemic pulmonary artery pressures, the RV is usually well adapted with marked concentric hypertrophy, limited dilatation and preserved systolic function. In contrast, maladaptive remodelling is characterized by progressive RV dilatation, eccentric hypertrophy and declining systolic function (Fig. 3 ). LaPlace's law states that wall tension (σ, afterload) is expressed as σ = P × R/h (where P = pressure, R = radius and h = wall thickness). Therefore, a non-dilated, concentrically hypertrophied RV minimizes ventricular wall stress.
A variety of cellular and molecular events are associated with the change to a maladaptive RV phenotype. Transition of myosin heavy chain (MHC) filaments to the β isotype is indicative of cardiac maladaptation. In RV heart failure (HF) secondary to PAH, α-MHC is significantly reduced and β-MHC is upregulated resulting in diminished systolic function. 10, 18 This may be a compensatory response to conserve energy as α-MHC is vastly dependent on adenosine triphosphate (ATP). In addition, in right HF, there is also a switch of myocardial metabolism from fatty acid oxidation to glycolytic pathways. 19, 20 This is considered to be a compensatory response (at least initially) to decrease myocardial oxygen consumption. 10 However, there is some evidence that metabolic switching with downregulation of mitochondrial metabolism may contribute to RV dysfunction. 21 In addition, alterations in neurohormonal signalling, oxidative stress, inflammation and angiogenesis also contribute to the development of RV maladaptation. [22] [23] [24] [25] Further research is needed to understand the processes of right heart adaptation.
The RV also has an anatomical disadvantage when compared with the left ventricle (LV). The orientation of left ventricular cardiomyocytes induces ventricular twisting during contraction to assist with augmenting ejection fraction. 26 In contrast, the orientation of RV fibres limit this ability, 27 minimizing the mechanisms by which the RV can maintain systolic function in the presence of increased afterload. These issues have been described in detail in previous reviews. 10, 28 The interdependent relationship between the LV and RV is well recognized. 29 Remodelling of the pressureloaded RV causes the interventricular septum to deviate to the left. As a consequence, there is associated left ventricular impairment and eventually, reduced left ventricular filling. In addition, dilation of the RV induced by exercise results in the compression of the LV. 30 Recent cardiac biopsies of PAH patients report~30% reduction in LV myocyte cross-sectional area when contrasted to a control group. 31 This atrophy may result from a reduction in LV preload.
Myocardial ischaemia
Patients with severe PAH often experience exertional angina that is attributed to RV ischaemia. Myocardial oxygen supply and demand in the RV contrast with the situation in the LV. 32 This may be another factor to explain the variance in right and left ventricular adaptation. Myocardial perfusion is dependent on the gradient between the aortic root pressure and intramural pressure. In PAH, systolic RV pressure becomes markedly elevated during systole, and right coronary blood flow adopts a biphasic pattern (similar to the LV) with a marked reduction in flow during systole. 33 This situation is likely to be exacerbated during exercise with a further increase in RV systolic pressure without a proportional increase in systemic blood pressure. An additional mechanism for RV ischaemia in the failing RV is capillary rarefaction (reduction in capillary density relative to myocardial mass). 24, 34 These changes result in myocardial ischaemia and perfusion abnormalities in PAH, 35 similar to pathology identified in the setting of a systemic RV (transposition of the great arteries). 36 
Ventriculoarterial uncoupling
Ventriculoarterial uncoupling is the physiological consequence of RV maladaptation. The relationship between ventricular contractility and afterload is referred to as 'ventriculoarterial coupling'. 10 In PAH, RV contractility is increased, but uncoupling occurs when the increase in contractility is inadequate to meet the demands of high afterload. 37, 38 This is manifested as attenuated RV contractile reserve during dobutamine stress. 7 The gold standard for assessing ventriculoarterial coupling is via analysis of pressure-volume loops, obtained invasively. This is difficult to accomplish in vivo as it requires manipulation of venous return to generate a set of pressure-volume loops. End-systolic ventricular elastance (Ees) is a load-independent measurement of ventricular contractility and is expressed as the slope defined by a set of end-systolic pressure-volume relationships. Arterial elastance (Ea) is represented as a lumped parameter of arterial afterload, expressed as end-systolic pressure over SV. The matching of contractility to its afterload or the coupling ratio is expressed as Ees/Ea. In compensated PAH, the Ees/Ea ratio is maintained but diminishes as RV decompensation ensues (Fig. 4) .
Patients with systemic sclerosis-associated PAH (SScPAH) experience a greater degree of RV dysfunction compared with idiopathic PAH patients. 39 Hsu et al. 39 demonstrated more significantly depressed contractile reserve and right ventricular-pulmonary artery (RV-PA) uncoupling in SScPAH, compared with idiopathic PAH patients despite similar resting haemodynamics. Myocardial fibrosis from systemic sclerosis is likely to be a contributing factor.
Even when RV-PA coupling is relatively preserved at rest, PAH patients have been shown to have an inability to increase Ees during exercise in face of the expected increase in Ea, leading to exercise-related deterioration in RV-PA coupling. 40 
Right ventricular dyssynchrony
Ventricular dyssynchrony describes uncoordinated contraction reducing effective pump function. RV dyssynchrony has been described in PAH patients resulting in compromised Qp and might be the result of mechanical (RV structural adaptation) 41 or electrical delay (right bundle branch block). 42 Patients with more severe RV dyssynchrony have poorer exercise capacity and a higher WHO-FC (World Health Organization Functional Class) level. 43 Badagliacca et al. 44 suggested that resting RV dyssynchrony is an independent predictor of peak VO 2 and postulated it is an important contributor to exercise intolerance.
Tricuspid regurgitation
The development of tricuspid regurgitation is common and has been associated with impaired exercise capacity in PAH patients. 6, 45 This problem develops because of annular dilation and secondary reduced coaptation of the tricuspid valve leaflets. Depending on severity, tricuspid regurgitation may result in an important reduction in pulmonary blood flow and also causes volume loading on an already dysfunctional RV.
Chronotropic response and cardiac autonomic function
With SV compromised by ventricular dysfunction, an increase in HR is the primary mechanism for patients to augment pulmonary blood flow 47 underlying the steeper slope of HR relative to VO 2 observed in this population. 48 Excessive HR reduces filling time, thus preload, further decreasing ejection fraction of the RV. 49 However, HR response in PAH is variable and chronotropic incompetence can occur in advanced PAH, possibly related to downregulation of β-adrenergic receptors in the RV. 50, 51 The inability to elicit a positive chronotropic response is also further attenuated if the patient is taking medications such as diltiazem. Provencher et al. 52 reported a correlation between chronotropic response to exercise (peak HR minus resting HR) and exercise capacity in PAH. Others have reported similar findings.
6,51,53 It is possible that this association relates to higher resting HR (attenuating the peak-resting difference) in the setting of more severe resting cardiac dysfunction, rather than reduced peak exercise HR but this is not clearly characterized in the literature. Delayed HR recovery activity indicates autonomic dysregulation and has been identified in patients with PAH. 51 Ramos et al. 54 proposed that a decrease in HR by 18 beats per minute (bpm) post-exercise is associated with enhanced exercise capacity in PAH subjects. However, objective values of normal HR recovery ranging from 12 bpm 55, 56 to 18 bpm 57 have been reported. Autonomic dysfunction is further corroborated by attenuated HR variability measures. Recently, the severity of impaired HR variability in PAH has been linked to WHO-FC. 58 Reduction in high-and lowfrequency parameters has been reported to be associated with a lower peak VO 2 when contrasted to age-sex match controls. 59 Further investigation of this measure of cardiac autonomic activity is required to understand. The clinical implications of these findings, that might simply reflect more advanced disease, are not yet fully characterized.
PULMONARY FACTORS
Although the pulmonary vasculature is highly abnormal in the setting of PAH, there is usually little derangement in mechanical lung function. Patients with PAH may occasionally display mild restriction in lung volumes but values are usually within normal limits. 60 Diffusing capacity for carbon monoxide (DL CO ) is mildly to moderately reduced; patients with SScPAH generally have lower DL CO values compared with idiopathic PAH. 61 An increase in small airway resistance has been shown, but the precise mechanism accounting for this remains unclear. 62, 63 Numerous pulmonary factors including arterial desaturation, ventilatory inefficiency and flow limitation have been suggested to contribute to impaired exercise capacity in PAH.
Pulmonary vasculopathy and endothelial dysfunction
Pulmonary vasculopathy is the central pathological feature of PAH and has been described as a process comparable to cancer where there is a mismatch between proliferation and apoptosis. 64 Endothelial dysfunction results in a dysregulation of pulmonary vascular control mediators and contributes to vascular remodelling [65] [66] [67] [68] [69] characterized by vasoconstriction, cellular hyperplasia, thrombosis and sclerosis, resulting in luminal obliteration. This combination of features reduces pulmonary vascular compliance. The onset of exercise immediately augments blood flow to the lungs. For an appropriate rise in Qp, the pulmonary vasculature must distend and recruit capacitance vessels to accommodate this increase in flow and maintain low pulmonary artery pressure. These mechanisms are impaired in PAH, resulting in a steep pulmonary artery pressure-flow response and increased RV afterload on exertion. 70 Recent elegant work has demonstrated that, whilst reduced pulmonary vascular compliance and increased stiffness are important, the interaction between the vasculature and the ventricle is probably more important than either factor in isolation (see ventriculoarterial coupling described above). 37 
Gas exchange and ventilation
Patients with PAH without coexistent lung disease or obesity have relatively preserved gas exchange at rest. Resting arterial blood gas in PAH is characterized by normal or mildly reduced partial pressure of oxygen (PaO 2 ) and low partial pressure of carbon dioxide (PaCO 2 ). Severe resting hypoxaemia is not usually a feature of PAH. Classical studies using the multiple inert gas elimination technique (MIGET) have demonstrated only mild ventilation-perfusion (V A /Q) abnormalities in Figure  4 Right ventricularpulmonary artery (RV-PA) coupling can be expressed as the ratio of end-systolic ventricular elastance (Ees) over arterial elastance (Ea). Ees is defined by the slope of the end-systolic pressure-volume relationship generated by a family of pressure-volume loops at decreasing venous return and is a load-independent measure of contractility. Ea is calculated as end-systolic pressure over stroke volume (SV) and is a measure of the afterload seen by the right ventricle. RV-PA coupling can be conceptualized as the ratio of Ees/Ea, or in other words, right ventricular contractility adjusted for afterload. RV-PA coupling may be preserved during the early stages of the disease when the increase in contractility matches the rise in afterload. RV decompensation is characterized by progressive RV-PA uncoupling when increased contractility is no longer sufficient to match the afterload, resulting in a fall in SV. NYHA FC, New York Heart Association Functional Class.
PAH. [71] [72] [73] V A /Q profile in PAH retains a narrow unimodal distribution with a rightward shift to higher V A /Q units due to excessive ventilation, both at rest and during exercise.
During exercise, many PAH patients will exhibit arterial desaturation, although the severity of desaturation appears variable. Given the minimal disturbance in V A /Q inequality, arterial hypoxaemia in PAH during exercise is mainly explained by reduced mixed venous oxygen content resulting from widening of the systemic arterial-venous oxygen difference in a low Qp state. Occasionally, increased right-to-left shunt fraction and severe hypoxaemia are seen in PAH patients. Right-to-left shunting has typically been attributed to the opening of a patent foramen ovale, particularly during exercise when right atrial pressure may rise briskly relative to left atrial pressure. It is unclear whether intrapulmonary shunting also develops via small collateral arteriovenous channels that bypass gas exchange units. Finally, reduced DL CO reflects reduced capillary blood volume and reduced alveolar membrane diffusing capacity. 74 It is plausible that in the setting of a restricted pulmonary circulation, capillary transit time can be decreased sufficiently during exercise to result in diffusion limitation and contribute to exercise desaturation. 61 However, the existence of true diffusion limitation during exercise in PAH has not been proven.
A hallmark of PAH is hyperventilation and ventilatory inefficiency. Hyperventilation and increased respiratory drive contribute to dyspnoea in PAH. 75 During exercise, VE/VCO 2 , a measure of ventilatory efficiency, is elevated when either measured at anaerobic threshold or expressed as the slope of minute ventilation (VE) versus carbon dioxide production (VCO 2 ). Increased VE/VCO 2 at anaerobic threshold has been shown to correlate with functional capacity and outcomes in PAH. 6, 76 Although ventilatory inefficiency is traditionally attributed to increased physiological dead space due to vascular obliteration, this alone cannot account for the degree of excessive ventilation observed in PAH. True hyperventilation occurs in PAH as PaCO 2 has consistently been found to be low during exercise. Arterial oxygen desaturation during exercise may contribute to increased respiratory drive, but hyperventilation occurs in PAH patients even in the absence of arterial hypoxaemia that is severe enough to trigger reflex hyperventilation. Similar to patients with chronic HF, enhanced chemosensitivity is now believed to be a major mechanism leading to hyperventilation in PAH. 77 The precise mechanisms which mediate enhanced chemosensitivity in PAH remain to be elucidated. Despite the marked hyperventilation, it is unusual for patients with PAH to reach ventilatory limitation during exercise where ventilation encroaches on maximal voluntary ventilation (MVV).
The presence of expiratory flow limitation has been documented in a subset of PAH patients in the absence of chronic obstructive pulmonary disease (COPD) or smoking history and may result in dynamic hyperinflation and contribute to the intensity of dyspnoea measured by the Borg scale. 62 The cause of expiratory flow obstruction is unknown.
Respiratory muscle dysfunction
Respiratory muscle dysfunction is increasingly recognized as having an important role in PAH-exercise limitation, although the pathophysiology is poorly understood. During near-maximal exercise,~15% of Qp is directed to the respiratory muscles 78 ; it is possible that these muscles are affected by reduced blood flow in the setting of PAH.
Meyer et al. 5 were the first to report respiratory muscle dysfunction in idiopathic PAH patients, assessed by volitional techniques (mouth occlusion pressure). Respiratory muscle dysfunction assessed using nonvolitional measures (trans-diaphragmatic pressure and twitch mouth pressure) has been shown in chronic thromboembolic PH (pulmonary hypertension) subjects. 79 de Man et al. 80 reported > 50% reduction in force generating capacity of the diaphragm in six PAH subjects. In addition, atrophy of the diaphragm characterized by a significant decrease in muscle fibre crosssectional area when contrasted to controls was demonstrated. Breda et al. 53 found an association between peripheral muscle strength and maximal inspiratory pressure (MIP) suggesting the respiratory muscles may influence exercise capacity. These findings were recently corroborated by a Turkish group that reported a correlation between 6-min walk distance (6MWD), physical activity scores and MIP. 81 Weak respiratory muscles may impair the function of the respiratory muscle pump or 'thoracic bellows'. During inspiration, there is an increase in negative intrathoracic pressure. This generates a pressure gradient to draw blood back to the right atrium and increases right ventricular SV. By augmenting the respiratory bellows, pulmonary blood flow may be enhanced (Fig. 5 ). This might be especially important in the setting of increased PVR and/or RV impairment.
Strengthening the respiratory muscles has been reported to improve exercise tolerance, QOL and reduce symptoms in patients with COPD, HF and PAH. In 2015, Saglam et al. 82 implemented isolated respiratory muscle training (RMT) in PAH (n = 14 intervention and n = 15 sham). They reported increases in inspiratory muscle strength and an average improvement of 50 m in walking distance after a 6-week inspiratory muscle training programme. This increase is comparable to current drug therapies and suggests RMT may be a feasible treatment modality. Further randomized control trials should be conducted to determine the mechanisms for improvement, safety and efficacy of RMT in this population.
IRON DEFICIENCY AND ANAEMIA
Sufficient iron stores are essential for the function of haemoglobin, myoglobin and oxidative enzymes. In a series of 70 idiopathic PAH subjects, 43% were reported to have iron deficiency. 83 Patients who had iron deficiency illustrated a reduction in 6MWD (390 m) in contrast to those who were not iron deficient (460 m). 83 This was independent of the presence of anaemia and consistent with findings in individuals with chronic HF. 83 In 2011, Rhodes et al. 84 also reported a negative correlation between iron deficiency evaluated by elevated soluble transferrin receptor and exercise capacity. Twelve weeks of intravenous iron therapy improved submaximal endurance capacity. 85 Others have also documented improvements in exercise capacity with iron supplementation. 86 Further research is required to understand the mechanisms by which iron deficiency and anaemia impact upon exercise capacity.
SKELETAL MUSCLE FACTORS
The underlying mechanisms for muscle dysfunction in this population are complex and not yet fully characterized. Dysfunction may be attributed to deconditioning, systemic inflammation, low Qp, chronic acidosis, sympathetic upregulation and impaired oxygen extraction within skeletal muscles.
Physical inactivity spiral deconditioning and frailty
The role of physical inactivity in muscle atrophy is generally underappreciated. Inactivity induces skeletal muscle atrophy, reduced contractility and myocyte fibre transition. [87] [88] [89] As symptoms intensify, patients avoid activity, promoting the onset of dyspnoea and fatigue. Consequently, a physical inactivity and atrophy spiral is established and symptoms are present even on light exertion. Exercise interventions can improve muscle properties.
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Skeletal muscle abnormalities
Skeletal muscle abnormalities have only recently been recognized as important in the pathophysiology of exercise intolerance in PAH. 4, 53, 93, 94 In 2007, Bauer et al. 4 were the first to report that skeletal muscle impairment existed in idiopathic PAH subjects and correlated with exercise intolerance (6MWD). Following this, findings of atrophy, impaired oxygen extraction, high anaerobic enzyme profile, diminished angiogenesis and reduced contractility have been reported. 4, 53, [93] [94] [95] It has been proposed that the pathological changes within skeletal muscle reflect a systemic myopathy comparable to HF. The simultaneous findings of respiratory muscle weakness and reduced maximal isometric forearm strength support this notion, and a correlation between the two has been reported. 4 This may contrast to other pulmonary conditions, such as COPD, where important peripheral muscle dysfunction exists 96, 97 with sparing of the respiratory muscles. 98, 99 In COPD, the influence of dynamic hyperinflation alters respiratory muscle length resulting in attenuated MIP and MEP (maximum expiratory pressures). CD31 + promotes neovascularization and miR-126 (microRNA-126) is well established to be proangiogenic. MiR-126 expression and CD31 + cells are diminished in skeletal muscle in the setting of PAH, and skeletal muscle capillary density correlates with exercise capacity and muscle strength. 100, 101 The presence of capillary rarefaction decreases transit time and increases the diffusion distance of erythrocytes to the mitochondria contributing to the abnormal arterialvenous difference commonly observed. In addition, low Qp establishes a hypoxic physiological environment during times of increased metabolic demand. This combines with impaired skeletal muscle oxygen extraction to reduce maximal exercise capacity in PAH. Oxidative stress may also be accentuated in the presence of mitochondrial dysfunction. 29 The impairment of microvascular oxygen delivery and intrinsic muscle dysfunction may account for the observed delay in VO 2 kinetics during the onset of exercise. 6, 102 Systemic inflammation is a prevalent finding in certain chronic disease states. It is known that inflammation has a catabolic effect on skeletal muscles. Elevated inflammatory cytokines including interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) may play a role in inducing skeletal muscle atrophy and contractile dysfunction. [103] [104] [105] Batt et al. 93 investigated the molecular basis of skeletal muscle dysfunction in 12 PAH patients. Levels of phosphorylated Akt and p70S6 kinase were reduced compared with controls reflecting dysregulation in protein synthesis pathways. The group also found evidence of proteasome-mediated muscle proteolysis. These findings may explain pathogenesis of muscle atrophy.
Similar to HF and COPD, there is evidence of fibre type transition in PAH peripheral muscles. The lower ratio of oxidative type I fibres and transition to type II fibres suggests a preference for anaerobic metabolism. 94 In addition, enzyme profiles (higher PFK:HADH (phosphofructokinase/3-hydroxyacyl-CoA-dehydrogenase ratio)) are inclined to stimulate anaerobic metabolism. 94 The deficiency in oxidative metabolism results in the reduction of aerobic ATP regeneration. 6 The cumulative effect results in a lower anaerobic threshold and earlier onset of metabolic acidosis from ATP hydrolysis, a major factor in fatigue and premature termination of exercise. 6 Further contributing to decreased muscle strength is dysfunctional excitation-contraction coupling as evidenced by RyR1(ryanodine receptor 1) hyperphosphorylation that may denote sarcoplasmic reticulum Ca 2+ sequestration. 93 The contribution of skeletal muscle to venous return and central haemodynamics is often overlooked as a factor that limits exercise capacity in chronic disease. The human cardiovascular network is a closed system, and thus the movement of fluids is influenced by a pressure gradient. The peripheral muscle pump is a critical mechanism required to increase Qp at the onset of erect physical activity; the heart is unable to increase Qp by more than a few percent independently without the assistance of peripheral muscle contractions to squeeze blood back to the heart. 106 Peripheral muscle dysfunction in PAH may inhibit the effectiveness of this mechanism. Whilst augmentation of the peripheral muscle pump has been shown to improve exercise capacity in the setting of complex heart disease, 107 the effects in the setting of a failing RV with raised filling pressure and afterload are unknown.
PERIPHERAL ENDOTHELIAL DYSFUNCTION
Although less extensively studied, there is also evidence of systemic endothelial dysfunction in PAH patients and correlation with disease severity and exercise capacity. 108, 109 During exercise, Qp is directed to support the recruitment of muscles and an increased metabolic demand. This is the result of a fine balance between vasoconstriction and vasodilation that translocates blood away from non-essential visceral organs to active skeletal muscles preventing premature fatigue. In addition, augmenting flow to the skin is required for effective thermoregulatory control. Endothelial dysfunction can disrupt this homeostatic process resulting in delayed or reduced flow which has also been demonstrated in PAH patients. 110 
METABOREFLEX 'MUSCLE HYPOTHESIS'
Consistent reports of skeletal muscle dysfunction have resulted in the notion of a 'muscle hypothesis'. 111 The muscle hypothesis attributes the symptoms of fatigue and dyspnoea to the metaboreflex. 111 This reflex is well established in other clinical populations including chronic HF and COPD, but has not been comprehensively investigated in PAH. The metoboreflex is induced by an accumulation of metabolic byproducts and results in sympathetic hyperactivity, promoting dyspnoea and hypoperfusion. 112 Low Qp, impairment of angiogenesis and hyperaemia further amplifies this reflex as the removal of byproducts is impeded. It is more likely that this metabolite-induced upregulation of sympathetic activity is ensued by the respiratory muscles in contrast to locomotor muscles, as the former are generally more sensitive to metabolites and fatigue. 113 This reflex stimulates vasoconstriction and a redirection of blood flow from locomotor muscles to the fatiguing respiratory muscles and amplifies the perception of leg fatigue. 78, 114 CONCLUSION PAH patients experience significant exercise intolerance that impacts upon QOL and prognosis. This reduction in exercise capacity relates to a complex interplay of factors. The literature to date has focused mainly on the effects of the cardiopulmonary system. While the capacity to maintain ventriculoarterial coupling is likely the major contributing feature, more recently the role of peripheral factors, such as dysfunction of the respiratory and peripheral muscles, have been recognized and may provide additional therapeutic avenues to improve exercise capacity. Further research to unravel these mechanisms and investigate interventions focused on improving skeletal and respiratory muscle function is warranted.
